Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation

被引:188
作者
Utsunomiya, A
Miyazaki, Y
Takatsuka, Y
Hanada, S
Uozumi, K
Yashiki, S
Tara, M
Kawano, F
Saburi, Y
Kikuchi, H
Hara, M
Sao, H
Morishima, Y
Kodera, Y
Sonoda, S
Tomonaga, M
机构
[1] Imamura Bun In Hosp, Dept Hematol, Kagoshima 8900064, Japan
[2] Nagasaki Univ, Inst Atom Dis, Dept Hematol, Mol Med Unit, Nagasaki 852, Japan
[3] Kagoshima Univ, Fac Med, Dept Internal Med 2, Kagoshima 890, Japan
[4] Kagoshima Univ, Fac Med, Dept Virol, Kagoshima 890, Japan
[5] Kagoshima City Hosp, Kagoshima, Japan
[6] Kumamoto Natl Hosp, Inst Clin Res, Kumamoto, Japan
[7] Oita Prefectural Hosp, Dept Hematol, Oita, Japan
[8] Oita Med Univ, Blood Transfus Serv, Oita, Japan
[9] Ehime Prefectural Cent Hosp, Matsuyama, Ehime, Japan
[10] Meitetsu Hosp, Dept Hematol, Nagoya, Aichi, Japan
[11] Aichi Canc Ctr, Dept Hematol & Chemotherapy, Nagoya, Aichi, Japan
[12] Japanese Red Cross Nagoya First Hosp, Div Hematol, Nagoya, Aichi, Japan
关键词
ATL; allo-SCT; allo-BMT; allo-PBSCT; HTLV-I proviral DNA;
D O I
10.1038/sj.bmt.1702731
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Adult T cell leukemia/lymphoma (ATL) is a poor prognosis T cell malignancy. In order to improve the outcome, we employed allogeneic stem cell transplantation (allo-SCT) for ATL in 10 patients, nine of whom were from HLA-identical siblings and one from an unrelated donor, Conditioning regimens varied among the patients except that all received total body irradiation. The patients tolerated the regimens well with mild, if any toxicity, and engraftment occurred in all cases. Median leukemia-free survival after allo-SCT was 17.5+ months (range 3,7-34,4+), Six of the 10 patients developed acute GVHD tone case each with grade I, III or IV, and three cases with grade II) and three patients developed extensive chronic GVHD, Four patients died after allo-SCT during the study period from either acute GVHD (grade IV), pneumonitis, gastrointestinal bleeding or renal insufficiency. Two of the 10 cases with no symptoms of GVHD relapsed with clinical ATL, These results strongly suggest that allo-SCT may improve the survival in ATL if a controlled degree of GVHD develops.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 21 条
  • [1] Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation
    Borg, A
    Yin, JAL
    Johnson, PRE
    Tosswill, J
    Saunders, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 94 (04) : 713 - 715
  • [2] TREATMENT OF ADULT T-CELL LEUKEMIA-LYMPHOMA WITH A COMBINATION OF INTERFERON-ALFA AND ZIDOVUDINE
    GILL, PS
    HARRINGTON, W
    KAPLAN, MH
    RIBEIRO, RC
    BENNETT, JM
    LIEBMAN, HA
    BERNSTEINSINGER, M
    ESPINA, BM
    CABRAL, L
    ALLEN, S
    KORNBLAU, S
    PIKE, MC
    LEVINE, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (26) : 1744 - 1748
  • [3] Treatment for adult T-cell leukemia
    Hanada, S
    Utsunomiya, A
    Suzuki, S
    Uozumi, K
    Makino, T
    Arima, T
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (Suppl 1) : S47 - S50
  • [4] ADULT T-CELL LEUKEMIA - ANTIGEN IN AN ATL CELL-LINE AND DETECTION OF ANTIBODIES TO THE ANTIGEN IN HUMAN-SERA
    HINUMA, Y
    NAGATA, K
    HANAOKA, M
    NAKAI, M
    MATSUMOTO, T
    KINOSHITA, KI
    SHIRAKAWA, S
    MIYOSHI, I
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (10): : 6476 - 6480
  • [5] Ikeda K, 1999, INT J CANCER, V82, P599, DOI 10.1002/(SICI)1097-0215(19990812)82:4<599::AID-IJC21>3.0.CO
  • [6] 2-R
  • [7] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [8] OVEREXPRESSION OF P-GLYCOPROTEIN IN ADULT T-CELL LEUKEMIA
    KATO, S
    NISHIMURA, J
    MUTA, K
    YUFU, Y
    NAWATA, H
    IDEGUCHI, H
    [J]. LANCET, 1990, 336 (8714) : 573 - 573
  • [9] Eradication of human T-lymphotropic virus type 1 by allogeneic bone-marrow transplantation
    Kawa, K
    Nishiuchi, R
    Okamura, T
    Igarashi, H
    [J]. LANCET, 1998, 352 (9133) : 1034 - 1035
  • [10] Phase I trial of recombinant immunotoxin anti-Tac(Fv)PE38 (LMB-2) in patients with hematologic malignancies
    Kreitman, RJ
    Wilson, WH
    White, JD
    Stetler-Stevenson, M
    Jaffe, ES
    Giardina, S
    Waldmann, TA
    Pastan, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) : 1622 - 1636